

## **DRUG PRIOR AUTHORIZATION COMMITTEE MEETING**

**March 21, 2019**

**MoHealthNet Howerton Building,  
Conference Room 202,  
Jefferson City, MO**

### **Committee Members Present**

Conrad Balcer, D.O., Chair  
Laura Kingsley, Pharm D  
Jennifer Kemp-Oestreich, Pharm D  
Pat Bryant, Pharm D  
Matthew Stinson, MD

### **Guest of Committee Member**

Pamela Maynez, Pharm D-guest of Pat Bryant

### **MO HealthNet Staff Present:**

Mark Roaseau, R.Ph, Clinical Pharmacist  
Sharie Hahn, Special Counsel  
Elizabeth Sissom, RN, Clinical Management  
Angela Wilson, Pharmacy Operations Manager  
Beth Mitchell, Administrative Assistant  
Mitch Ruth, Pharmacy Fiscal Unit Manager

Dr. Timothy Kling, MD, Assistant Medical Director

Lisa E. Smith, Program Development Specialist

Jackie Hickman, Drug Rebate Unit Supervisor

Kari Ballew, Drug Rebate Unit Medicaid Specialist

Elizabeth Short, Program Specialist

### **Contractors in Attendance:**

Joshua Moore, Pharm D, Conduent

Luke Boehmer, Pharm D, Conduent

Jennifer Colozza, Pharm D, Conduent

Crystal Wickers, Conduent

Janelle Sheen, Pharm D, Conduent

Olivia Rush, Pharm D, Conduent

Geri Roling, Wipro

Chelsea Pendleton, Wipro

### **Others Attending:**

Michael Lafond, abbvie

Camille Kerr, Amgen

Cristina Brandmeyer, Amgen

Kim Witte, Avexis

Aaron Shaw, BI

Mark Friederich, D2

Toni Pegues, Genetech

Garth Wright, Genetech

Kim Moore, GLO

Robert Welch, Greenwich

Shannon Meyer, Greenwich

Brent DePriest, GSX

Meghan Kerrigan, Merck

Don Kempin, Novo Nordisk

Jim Baumann, Pfizer

Chris Toekalakir, RB

Donna Osterlund, Sanofi Genzyme

Michael Holmes, Sunovion

Chris Stanfield, Supernus

Maggie Murphy, Teva

Doug Wood, Viiv Healthcare

<b>Welcome, Introductions and Opening Remarks</b>	Conrad Balcer, Chair, called the meeting to order. Mark Roaseau introduced himself and started the introductions and opening remarks.
<b>Minutes Approval</b>	Minutes of the September 2018 Drug PA meeting were reviewed and approved. Pat Bryant made the motion and Laura Kingsley seconded the motion.
<b>Pharmacy Program/Budget Update</b>	Mitch Ruth presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.
<b>Old Business</b>	
<b>Old Business Implementation Schedule</b>	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included June/July, 2018 PDL decisions to be implemented October 4, 2018. Pending ratification, PDL decisions from the September 2018 Drug PA Committee meeting will be implemented January 2019. Schedules may be found on the MHD web page at  <a href="https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf">https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf</a>
<b>New Business</b>	

<b>New Drug Review</b>	<p>Mark Roaseau reviewed the new products identified for the quarter July, August and September, 2018 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> <li>● <b>Discussion</b> – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members’ meeting packet for discussion and action. This listing was also provided as a handout to all attending.</li> <li>● <b>Public Hearing</b> – Zac Henney represented AkaRx, Inc. commented on Doptelet, Laura Hill represented AbbVie commented on Humira, Orliissa. Andrew Kucharski, PHD represented Alnylam Pharmaceuticals commented on Onpattro</li> <li>● <b>Decision</b> – Members voted to accept the new product recommendations as presented</li> </ul>
<b>Clinical Edits</b>	
<b>Benzodiazepines Clinical Edit</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document. ●</li> <li>● <b>Public Hearing</b> –.Laura Hill represented AbbVie commented on Orliissa. ●</li> <li>● <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>
<b>Clobazam Clinical Edit</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document. ●</li> <li>● <b>Public Hearing</b> – No comments entered ●</li> <li>● <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>
<b>Epidiolex Clinical Edit</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document. ●</li> <li>● <b>Public Hearing</b> – Andrew Kucharski commented on Onpattro. ●</li> <li>● <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>
<b>Morphine-milligram-Equivalent Accumulation Edit</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document. ●</li> <li>● <b>Public Hearing</b> – Andrew Kucharski commented on Onpattro. ●</li> <li>● <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>

<b>Nocturnal Plyuria Clinical Edit (New)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document. ●</li> <li>● <b>Public Hearing</b> – Andrew Kucharski commented on Onpattro. ●</li> <li>● <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>
<b>Systemic Antifungals Clinical Edit (New)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the new criteria in this document. ●</li> <li>● <b>Public Hearing</b> – Andrew Kucharski commented on Onpattro. ●</li> <li>● <b>Decision</b> – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List (PDL)</b>	
<b>Actinic Keratosis Agents - Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred. ●</li> <li>● <b>Public Hearing</b> – No Comments Entered ●</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Androgenic Agents - Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Antibiotics - Inhaled</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – Justin Barnes represented Trsipharma commented on Dynavael XR.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Antihistamines - Intranasal</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Antihistamines - Low-Sedating (2nd Generation)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Antihistamines/Decongestants - Low-Sedating</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – Christy Skibicki, MD represented Perseris, Erin Hohman represented Invega Sustenna/Invega Trainza, Gena Terlizza, NAMI shared personal experience, Dr. Shelly Thompson represented Aristada and Aristada Intitio, Rick Kegler represented Abilify maintena and Rexulti.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Antihistamines - Ophthalmic</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Antiparasitics - Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Antivirals - Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered. ●</li> <li><b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Atopic Dermatitis Agents (Topcial Immunomodulators)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – Charlie Kelly represented Pharma, Phil Arnold represented Shire</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Benzoyl Peroxide/Antibiotic Combination - Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No Comments were entered. ●</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Beta-Adrenergic Agents (Long-Acting)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments were entered. ●</li> <li><b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Beta-Adrenergic Agents - Nebulized</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments were entered. ●</li> <li><b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Beta-Adrenergic Agents (Short-Acting)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments were entered. ●</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<p><b>Calcitonin Gene-Related Peptide Inhibitor Agents (New)</b></p>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<p><b>COPD Anticholinergic Agents</b></p>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – Dr. Shelly Thompson represented Alkermes, Inc., Christy Skibicki, MD represented Indivior, Gerri Lynn Gothrie represented Orexo. Letter from American Society of Addiction Medicine and letter from Representative Holly Rehder</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<p><b>Corticosteroids - Oral Inhaled</b></p>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<p><b>Corticosteroids – Ophthalmic “Soft” Steroids and Intravitreal Implants (New)</b></p>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<p><b>Corticosteroids – Topical</b></p>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Cough &amp; Cold Products</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Cough &amp; Cold Opioid Combination Products</b>	<p><b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</p> <ul style="list-style-type: none"> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Epinephrine Self-Injectable Products</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Public Hearing</b> – No comments were entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Fluoroquinolones – Ophthalmic</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Fluoroquinolones – Otic</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Herpes Antivirals – Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>



<b>Leukotriene Modifiers – Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Mast Cell Stabilizers – Ophthalmic</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>NSAIDs – Ophthalmic</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Pancreatic Enzymes</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Prostaglandin Agonists (Glaucoma Agents)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Psoriasis Agents – Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Psoriasis Agents – Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Retinoids – Topical</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ulcerative Colitis Agents – Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ulcerative Colitis Agents - Rectal</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau stated there are no changes recommended for this class.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List Announcement</b>	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page:</p> <p><a href="http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf">http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</a></p>
<b>Conduent Update</b>	<p>Conduent did present the following items for review. These items were included in the packet for the meeting. Here is the list:</p> <ul style="list-style-type: none"> <li>• Call Center Statistics, Claims, Spend, and Diagnosis information for the SSRI's and SNRI's.</li> <li>• New Drug Summary.</li> </ul>

<p><b>Program Utilization: Top 25 Drugs Summary</b></p>	<p>The Top 25 Drugs Summary Reports for the 3<sup>rd</sup>, &amp; 4th quarter of fiscal year 2018 and 1<sup>st</sup> and 2<sup>nd</sup> quarters for Fiscal year 2019 were provided in the packets for review. Two versions were provided: one report ranked drug spend by dollars and the other by utilization/claims.</p>
<p><b>Call Center Statistics/MO User Stats/PDL Website-New PDL Listing and Searchable Database Manual</b></p>	<p>In the packets provided for the meeting were the following handouts and reports:</p> <ul style="list-style-type: none"> <li>• A handout detailing pharmacy help desk call center activity.</li> <li>• MO User Stats</li> <li>• Reports were also provided detailing the number and type of prescribers and active users on Cyber Access.</li> <li>• Preferred Drug List</li> </ul> <p>Searchable Database and Static Document Manual</p>
<p><b>Adjourn</b></p>	<p>The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call) The next meeting of the <b>Drug Prior Authorization Committee</b> is scheduled for <b>March 21, 2019 at the Missouri Coalition for Community Behavioral Healthcare Building, Lower Level CEO Room, 221 Metro Drive, Jefferson City, MO.</b></p>

<b><u>Roll Call for March 21, 2019</u></b>							
<b><u>Member</u></b>	<b>Minutes</b>	<b>New Drugs</b>	<b>Benzodiazepines Clinical Edit (New)</b>	<b>Clobazam Clinical Edit (New)</b>	<b>Epidiolex Clinical Edit (New)</b>	<b>Morphine- Milligram- Equivalent Accumulation Edit</b>	<b>Nocturnal Polyuria Clinical Edit (New)</b>
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	MY	SY	SY	Y	MY	Y	Y
Laine Young-Walker, M.D.	A	A	A	A	A	A	A
Morgan Sperry, Pharm D-Alternate							
Jennifer Kemp- Oestreich, Pharm D	Y	MY	MY	SY	Y	Y	Y
Laura Kingsley, Pharm D	Y	SY	Y	Y	MY	Y	SY
Matthew Stinson, MD	Y	Y	Y	Y	Y	SY	MY

<u>Member</u>	Actinic Keratosis Agents – Topical	Androgenic Agents – Topical	Antibiotics - Inhaled	Antifungals (Onychomycosis Agents) – Oral	Antifungals – Topical	Antihistamines – Intranasal	Antihistamines – Low-Sedating (2nd Generation)
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	Y	MY	Y	SY	Y	MY	MY
Laine Young-Walker, M.D.	A	A	A	A	A	A	A
Morgan Sperry, Pharm D-Alternate							
Jennifer Kemp-Oestreich, Pharm D	Y	MY	SY	Y	Y	Y	Y
Laura Kingsley, Pharm D	Y	SY	MY	Y	Y	Y	SY
Matthew Stinson	Y	Y	MY	MY	MY	SY	Y

<u>Member</u>	Antihistamines – Ophthalmic	Antiparasitics – Topical	Antivirals - Topical	Atopic Dermatitis Agents (Topical Immunomodulators)	Benzoyl Peroxide/Antibiotic Combinations – Topical	Beta-Adrenergic Agents (Long-Acting)	Beta-Adrenergic Agents – Nebulized
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	Y	Y	SY	SY	Y	MY	Y
Laine Young-Walker, M.D.	A	A	A	A	A	A	A
Morgan Sperry, Pharm D-Alternate							
Jennifer Kemp-Oestreich, Pharm D	MY	Y	Y	Y	MY	SY	Y
Laura Kingsley, Pharm D	SY	MY	Y	MY	SY	Y	MY
Matthew Stinson, MD	Y	Y	MY	Y	Y	Y	SY

<u>Member</u>	Calcitonin Gene-Related Peptide Inhibitor Agents (New)	COPD Anticholinergic Agents	Corticosteroids – Intranasal	Corticosteroids – Ophthalmic “Soft” Steroids and Intravitreal Implants (New)	Corticosteroids – Topical	Cough & Cold Products	Cough & Cold Opioid Combination Products
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	Y	SY	MY	SY	MY	MY	MY
Laine Young-Walker, M.D.	A	A	A	A	A	A	A
Morgan Sperry, Pharm D-Alternate							
Jennifer Kemp-Oestreich, Pharm D	Y	Y	Y	Y	MY	SY	Y
Laura Kingsley, Pharm D	SY	Y	SY	Y	Y	MY	SY
Matthew Stinson, MD	MY	MY	Y	Y	Y	Y	Y

<b>Member</b>	<b>Fluoroquinolones – Ophthalmic )</b>	<b>Fluoroquinolones – Otic</b>	<b>Herpes Antivirals – Oral</b>	<b>Leukotriene Modifiers – Oral</b>	<b>Mast Cell Stabilizers – Ophthalmic</b>	<b>NSAIDs – Ophthalmic</b>	<b>Pancreatic Enzymess</b>
<b>Conrad Balcer, D.O.</b>	Y	Y	Y	Y	Y	Y	Y
<b>Pat Bryant, Pharm D</b>	MY	Y	Y	Y	SY	MY	MY
<b>Laine Young-Walker, M.D.</b>	A	A	A	A	A	A	A
<b>Morgan Sperry, Pharm D-Alternate</b>							
<b>Jennifer Kemp-Oestreich, Pharm D</b>	Y	MY	MY	MY	Y	SY	Y
<b>Laura Kingsley, Pharm D</b>	SY	Y	Y	SY	Y	Y	SY
<b>Matthew Stinson, MD</b>	Y	SY	SY	Y	MY	Y	Y

<b>Member</b>	<b>Psoriasis Agents- Oral</b>	<b>Psoriasis Agents- Topical</b>	<b>Retinoids – Topical</b>	<b>Ulcerative Colitis Agents – Oral</b>	<b>Ulcerative Colitis Agents - Rectal</b>	<b>Meeting Adjourn</b>
<b>Conrad Balcer, D.O.</b>	Y	Y	Y	Y	Y	Y
<b>Pat Bryant, Pharm D</b>	SY	SY	SY	Y	MY	SY
<b>Laine Young-Walker, M.D.</b>	A	A	A	A	A	A
<b>Morgan Sperry, Pharm D-Alternate</b>						
<b>Jennifer Kemp-Oestreich, Pharm D</b>	Y	Y	Y	MY	Y	Y
<b>Laura Kingsley, Pharm D</b>	MY	MY	Y	Y	SY	Y
<b>Matthew Stinson, MD</b>	Y	Y	SY	SY	Y	MY

**Roll Call**

**Abbreviations:**

**A-Absent**

**AL-Alternate**

**R-Ratify**

**M-Motion**

**S-Second**